Takeda Gives Mellinnium Task To Select Best Cancer Drug Candidates
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical is turning over the decision-making about its pipeline of oncology drugs to its American biotech subsidiary, Millennium Pharmaceuticals. Takeda has 15 drugs for treating cancer in clinical trials, but has decided to let Mellinnium draw on its expertise and technology to select the best candidates from among them and speed their development. Takeda is more familiar with hypertension and diabetes drugs, but several best-sellers in those groups face patent expirations next year. (Click here for more - a subscription may be required